Creating Glaxo Wellcome
Executive SummaryGlaxo took over Wellcome to boost profits at risk from the Zantac patent expiration. But its R&D managers used the tumult and pain caused by the deal to revitalize an organization which had grown complacent and was ill-equipped to exploit the new technologies which were industrializing drug discovery. Productivity is way up--with no increase in budget. But has Glaxo Wellcome really accomplished its mission or is a continuing series of cost-squeezing mergers still inevitable?
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 4)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this fourth installment of a 10-part series, the experts address so-called back rooms used by manufacturers during an inspection.
Recruiting generics firms to the AMR Industry Alliance is a key area of focus for the group as part of its efforts to cover a greater proportion of the global supply of antimicrobials, according to the Alliance’s latest report.